CLDN3 and esophageal adenocarcinoma: For example, CLDN3 positivity was described in 95% of 20 [37] and in 89% of 57 [38] esophageal adenocarcinomas (our study: 93.4%), 100% of 16 colorectal neuroendocrine tumors [39] (our study: 100%), and in 97% of 34 pulmonary adenocarcinomas [29] (our study: 96.2%).